Literature DB >> 15105060

Emetine ditartrate: a possible lead for emergency contraception.

P K Mehrotra1, S Kitchlu, A Dwivedi, P K Agnihotri, S Srivastava, R Roy, A P Bhaduri.   

Abstract

Interception of pregnancy in its initial stage is an attractive and viable approach to contraception. A chemical agent, taken within the first few days of missed menses, intercepts the conception, which is expelled with menstrual flow. The main targets of such agents are the uterus, blastocyst and the growing trophoblasts, whose nutritional requirement is inhibited. Our previous work has identified several nonsteroidal chemical entities as pregnancy interceptives in rodents and infrahuman primates. However, none reached clinical stage due to their ineffectiveness by oral route. Nevertheless, parallel to these rationally designed synthetic compounds, a program was ongoing to identify natural product(s) that can be used as interceptives. We are reporting for the first time the detailed profile of emetine ditartrate, a compound whose pregnancy interceptive efficacy has been studied in mouse, rat, hamster, guinea pig and rabbit by oral and intravaginal routes of administration. By the oral route, the compound caused 100% resorption of the fetuses in rat, hamster and guinea pig at 6.0, 5.0 and 3.0 mg/kg, respectively, on administration during peri- and early postimplantation periods of pregnancy (depending upon the day of implantation in each species). By intravaginal route, the compound was administered once in the form of a vaginal pessary on the day of implantation in respective species; interception of pregnancy was not achieved completely in rat and hamster at doses four to five times the oral dose in multi-day schedule. However, in guinea pig and rabbit it was fully effective at 7.0 and 70.0 mg/animal, respectively. The compound was devoid of estrogenic, antiestrogenic and progestational activity but possessed mild antiprogestational activity at the high dose in vivo. In in vitro assay, however, it did not show any significant binding to estrogen and progesterone receptors. The mode of action of the compound was found to be mainly on the uterus and early embryos around implantation, possibly on the trophoblasts and endometrial cells at the attachment site. The absence of 100% efficacy in rat and hamster by intravaginal route, but not by oral route, is possibly due to poor absorption of the compound through the vagina in these species. The guinea pig and rabbit, therefore, seem the better species for evaluating the efficacy of the compound administered by the vaginal route.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105060     DOI: 10.1016/j.contraception.2003.12.011

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation.

Authors:  Claudia Busonero; Stefano Leone; Filippo Acconcia
Journal:  Cell Oncol (Dordr)       Date:  2017-03-29       Impact factor: 6.730

2.  Borreria and Spermacoce species (Rubiaceae): A review of their ethnomedicinal properties, chemical constituents, and biological activities.

Authors:  Lucia Maria Conserva; Jesu Costa Ferreira
Journal:  Pharmacogn Rev       Date:  2012-01

3.  Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry.

Authors:  Shu Yang; Miao Xu; Emily M Lee; Xiangguo Qiu; Alexey V Terskikh; Hengli Tang; Hongjun Song; Wei Zheng; Kirill Gorshkov; Sergey A Shiryaev; Shihua He; Wei Sun; Yu-Shan Cheng; Xin Hu; Anil Mathew Tharappel; Billy Lu; Antonella Pinto; Chen Farhy; Chun-Teng Huang; Zirui Zhang; Wenjun Zhu; Yuying Wu; Yi Zhou; Guang Song; Heng Zhu; Khalida Shamim; Carles Martínez-Romero; Adolfo García-Sastre; Richard A Preston; Dushyantha T Jayaweera; Ruili Huang; Wenwei Huang; Menghang Xia; Anton Simeonov; Guoli Ming
Journal:  Cell Discov       Date:  2018-06-05       Impact factor: 10.849

Review 4.  Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.

Authors:  Weibao Song; Hongjuan Zhang; Yu Zhang; Rui Li; Yanxing Han; Yuan Lin; Jiandong Jiang
Journal:  Front Med       Date:  2020-12-28       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.